Introduction
Aberrant Signal transducer and activator of transcription (Stat) activation has been identified in malignant cells from many cancers. Accordingly, activation of Stat transcription factors is involved in cell transformation induced by a number of oncogenic proteins such as v-Src, BCR/ABL, TEL-JAK2, v-Abl, and NPM/ALK. 1, 2 Stat activation is crucial for cell transformation by at least some of these, as oncogene induced cell growth is inhibited by transfection with dominant negative Stat mutants. [3] [4] [5] [6] Stat importance in neoplasia was highlighted by the observation that a constitutively active variant of Stat3 is itself oncogenic, as it induces transformation of fibroblasts and tumour formation in vivo. 7 Suppressors of cytokine signalling (SOCS) proteins are Statinduced negative regulators of the Jak/Stat signalling pathways. Since the cloning of SOCS-1, it has become evident that SOCS are important for proper control of cytokine and growth factor responses and absence of SOCS proteins leads to excessive cytokine signaling. [8] [9] [10] In contrast to Stats, only little is known about SOCS protein involvement in cancer. Owing to their capability to inhibit Stat activation, SOCS proteins are likely to be dysregulated in cells with constitutive active Stat factors.
Indeed, SOCS-1 gene silencing by DNA hypermethylation at the gene promoter region has been found in such diverse cancers such as hepatocellular carcinoma, multiple myeloma, acute myeloid leukemia (AML), pancreatic ductal neoplasms, and primary brain tumours. [11] [12] [13] [14] [15] Mouse embryo fibroblasts from SOCS-1 knockout mice are less sensitive to contact inhibition and more sensitive to oncogene-induced transformation, leading to the hypothesis that SOCS-1 is a tumour suppressor. 16 Furthermore, SOCS-1 inhibits cell growth or transformation induced by some, but not all, oncogenes.
17,18 SOCS-3 shares 35% homology with SOCS-1 and similar to SOCS-1, it is a potent inhibitor of Stat activation following stimulation with many different cytokines. 10 Interestingly, constitutive expression of SOCS-3 has been found in tumour cells from a number of malignancies including AML, cutaneous T-cell lymphoma (CTCL), and chronic myelogenous leukemia (CML). [19] [20] [21] We have previously shown that tumour cell lines established from CTCL patients have a constitutively active Stat3 and expression of several SOCS, 19, 22 highlighting the apparent paradox of how malignant cells can coexpress an active Stat3 and negative regulators of Stat activation such as SOCS. Since SOCS-3 expression is mediated by the constitutively active Stat3, 19 we speculated that the expressed SOCS-3 may either be structurally abnormal or, alternatively, display oncogenic rather than oncosuppressive properties. To explore these possibilities, we examined the structure of SOCS-3 as well as its effect on Stat3 activation, cell growth, and cytokine responses in the CTCL cells.
Materials and methods

Cell lines
Cell lines established from CTCL patients have previously been described. 23 MF2000 cells were stably transfected (electroporation) with inducible SOCS-3 using the T-Rext (Invitrogen, Carlsbad, CA, USA) system according to the manufacturer's instructions. All transfectants were maintained in RPMI 1640 (Sigma Chemical, St Louis, MO, USA) supplemented with 10% FBS (Life Technologies, Roskilde, Denmark), 2 mM L-glutamine (Sigma), 100 mg/ml penicillin/streptomycin (Sigma) and 70 mg/ml Zeocin (Invitrogen). Human T lymphocytes were purified from leukocyte-rich buffy coats of healthy blood donors (Blood-bank, State University Hospital, Copenhagen, Denmark) by density gradient centrifugation using Lymphoprep (Nycomed Pharma A/ S, Oslo, Norway). After removing adherent cells, lymphocytes were activated with 5 mg/ml of PHA-M (Roche, Mannheim, Germany) and cultured in RPMI 1640 medium supplemented with 10% human pooled serum (Blood-bank), 2 mM L-glutamine, 100 mg/ml penicillin/streptomycin, and 100 IU/ml human rIL-2 (Chiron, Emeryville, CA, USA) for 10-15 days. Cell cultures were 490% T cells (CD3 þ ) as determined by flow cytometric analysis. For induction of SOCS-3 expression, T cells were cultured in the absence of IL-2 overnight and then stimulated with 10 3 IU/ml human rIL-2, as previously described. 24 COS-1 cells were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin/streptomycin. COS-1 cells were transiently transfected with 5 mg DNA using Lipofectin (Invitrogen) and Optimem (Invitrogen). Human SOCS-3 construct was obtained by PCR cloning from cDNA from IL-2-stimulated human PLT cells 25 and inserted into the pcDNA4/TO/myc-His vector (T-Rex system) or the pEF vector. SOCS-3 F25D was obtained by insertion of a TT to GA mutation at position 73-74 in the cDNA, using the QuickChange s mutagenesis kit (Stratagene, La Jolla, CA, USA). All constructs were confirmed by sequencing. Myc-tagged SOCS-3 expression was induced by incubating the cells with 20 ng/ml tetracyclin (Tet) (Invitrogen) for the indicated periods of time.
Western blotting and antibodies
Cells were pelleted, lysed and subjected to Western blotting as previously described. 22, 26 Myc-Tagged SOCS-3 was immunoprecipitated using 5 mg anti-Myc (9E10) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Protein-A agarose beads (KemEn-Tec, Copenhagen, Denmark). Membranes were probed using antibodies specific for Myc (9E10), Anti-Stat1, anti-Stat6, and anti-SOCS-3 from Santa Cruz, anti-PY-Stat1 and anti-PY-Stat5 from New England Biolabs (Beverly, MA, USA), anti-PY-Stat3 from Nanotools (Denzlingen, Germany), anti-Stat3 and antiStat5 from Transduction Laboratories (Lexington, KY, USA), antiPhosphor-tyrosine (PY) 4G10 from Upstate Biotechnologies, and HRP-conjugated anti-rabbit Ig, HRP-conjugated anti-mouse Ig, or HRP-conjugated anti-goat Ig from Dako (Glostrup, Denmark) and evaluated using enhanced chemiluminescence (ECL) according to the manufacturers instructions (Amersham, Buckinghamshire, UK). IFNa was purchased from Schering-Plough (Kenilworth, NJ, USA), IL-2 from Chiron (Emeryville, CA, USA), and IL-4 from Leinco (Ballwin, MO, USA).
CFSE labelling of cells
Cells were washed in serum-free medium, stained with 5 mM CFSE (Molecular Probes, Eugene, OR, USA) for 10 min at 371C followed by washing and culturing in FBS-containing medium with/without 20 ng/ml tetracyclin to induce SOCS-3 expression. For the analysis of IFNa-mediated growth inhibition, 5000 U/ml IFNa was added to the cultures. Cell fluorescence was analysed by flow cytometry on day 0, 2, 3, and 4 of the cultures.
Results and discussion
Tumour cell lines, established from CTCL patients, have a constitutive active Stat3, leading to constitutive expression of SOCS-3 in these cells. 19, 22 SOCS proteins are negative regulators of Jak/Stat activation, 10 and SOCS-3 is thus expected to downregulate or turn off Stat3 activation when expressed in cells. However, this does not seem to be the case in CTCL cells. The inability of SOCS-3 to inhibit Stat3 activation in CTCL cells is unlikely to be due to insufficient expression of SOCS-3, as endogenous SOCS-3 expression in CTCL cells is comparable to or higher than that in nonmalignant peripheral blood T cells stimulated with IL-2 ( Figure 1, lanes 1-5) . Further, sequence analysis of SOCS-3 cDNA from the CTCL cells showed no deviations from the published cDNA sequence (data not shown), excluding the possibility of the constitutive Stat3 activation being caused by a lack of function mutation in SOCS-3. To investigate the impact of SOCS-3 on Stat3 activation and functional status in CTCL cells, we generated CTCL cells expressing an inducible wild-type (wt) SOCS-3 or a nonfunctional SOCS-3 mutant (F25D) as a negative control (Figure 1,  lanes 6 and 7) . Stat3 activation was examined in these CTCL cells after induction of exogenous SOCS-3 (Figure 2a) . However, expression of neither wt nor F25D SOCS-3 had any effect on Stat3 activation at any of the time points tested. Thus, after as long as 48 h of forced SOCS-3 expression, Stat3 phosphorylation Whole-cell lysates were subjected to Western blotting using the PYStat3 Ab. The membrane was subsequently stripped and reprobed using antibodies specific for Stat3 and Myc, respectively. (b) Cells were stained with CFSE before culturing with/without tetracyclin. Cell fluorescence was analysed on day 0 (grey), day 2 (solid line), and day 3 (broken line) by flow cytometric analysis.
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C Brender et al levels were not affected, indicating that Stat3 is activated in CTCL cells by a SOCS-3-resistant kinase. Next, we examined SOCS-3 impact on cell proliferation using cells labelled with CFSE at day 0. Figure 2b shows cell fluorescence on days 2 and 3 after SOCS-3 induction. No difference was seen when either wt or mutant SOCS-3 was induced as compared to the noninduced or mock-transfected cells. These data were confirmed by staining for DNA content, showing no difference in G1/G2 distribution or apoptosis between induced/noninduced cells (data not shown). Thus, in contrast to findings with the closely related SOCS-1 in other malignancies, SOCS-3 does not seem to act as a tumour suppressor in CTCL. Previous reports have shown that SOCS-3 is phosphorylated on tyrosine residues in response to cytokines and growth factors. 27, 28 Phosphorylation influences SOCS-3's ability to interact with the RasGAP and Elongin B/C proteins 28, 29 and is thus potentially important for proper function of SOCS-3. In our control experiment, treatment of COS-1 cells transiently transfected with wt SOCS-3 with the protein-tyrosine phosphatase inhibitor sodium pervanadate indeed resulted in detection of high levels of tyrosine phosphorylated SOCS-3 ( Figure 3a) . To investigate whether SOCS-3 is tyrosine phosphorylated in CTCL cells, SOCS-3 was immunoprecipitated and subjected to Western blotting using an anti-phosphotyrosine antibody (Figure 3b ). SOCS-3 phosphorylation was not detectable in untreated cells (lanes 3) but was evident in cells following treatment with pervanadate (lanes 4). This indicates that SOCS-3 becomes phosphorylated in CTCL cells similar to that in COS-1 cells and is subjected to the same regulatory mechanisms as exist in nonmalignant cells. However, further studies are needed to establish the exact mechanisms as well as the role of SOCS-3 phosphorylation, both in CTCL cells and in nonmalignant cells.
Loss of responsiveness to certain growth factors and cytokines plays an important role in oncogenesis by permitting the malignant cells to avoid growth inhibitory or differentiation signals. Although such unresponsiveness is frequently achieved by loss of cytokine receptor expression, 30, 31 other mechanisms including overexpression of a negative regulator of cytokine signalling may also play a role. We have previously shown that in CTCL cells transfected with a dominant negative Stat3, the absence of endogenous SOCS-3 coincides with increased IFNa signaling. 19 To provide direct evidence that SOCS-3 does indeed modulate the response to this cytokine, we examined IFNa responses in (i) wt CTCL, (ii) CTCL cells expressing inducible SOCS-3, and (iii) CTCL cells expressing the dominant negative Stat3 (Stat3D), which inhibits the endogenous SOCS-3 expression. 19 In agreement with the difference seen previously between SOCS-3hi and SOCS-3lo cells, 19 expression of SOCS-3 caused a marked reduction in IFNa-induced phosphorylation of both Stat1 and Stat3 (Figure 4a lanes 6 and 8, respectively) , whereas induction of the nonactive SOCS-3 mutant had no effect (lanes 10 and 12). As expected from the findings in nonmalignant T cells, wt SOCS-3 was able to block IL-2-induced Stat5 phosphorylation (Figure 4b ). In contrast, neither wt nor F25D SOCS-3 was able to inhibit IL-4-induced activation SOCS-3 expression inhibits Stat activation induced by IFNa and IL-2, but not IL-4. Cells were incubated for 6 h with tetracyclin to induce expression of SOCS-3, then stimulated with (a) 5000 U/ml IFNa, (b) 500 U/ml IL-2, or (C) 10 ng/ml IL-4 for 15 min at 371C. Whole-cell lysates were analysed by Western blotting, using the indicated antibodies. (Figure 4c) . Culturing of CTCL cells in the presence of IFNa caused a decrease in cell proliferation, which could be visualised by CFSE labelling of the cells (Figure 5a ). Overexpression of wt SOCS-3 (but not the inactive mutant) almost completely blocked the IFNa-induced growth inhibition. In contrast, inhibition of SOCS-3 expression by Stat3D increases the sensitivity to IFNa by more than 40% (Figure 5b ), confirming the involvement of SOCS-3 in regulation of biological responses induced by IFNa in CTCL cells.
No dominant negative effect was seen with SOCS-3 F25D in the CTCL cells, although an analogous mutation in SOCS-1 (SOCS-1 F59D) was previously reported to render SOCS-1 dominant negative. 34 Similarly, we saw no effect of SOCS-3 F25D on wt SOCS-3's ability to inhibit IFNa-induced Stat3 activation in cotransfection experiments in COS-1 cells (data not shown), indicating that SOCS-3 F25D does not act as a dominant negative mutant.
Acquired resistance to IFNa can be beneficial to tumour cells, permitting them to circumvent the antiproliferative effect of IFNa, an agent frequently used in therapy of CTCL and other malignancies. Accordingly, diminished effectiveness of IFNa therapy is seen in some CTCL patients, particularly in the advanced stages of the disease. 35 The cause of the decrease is currently uncertain and could in some cases be caused by loss of expression of relevant signalling molecules. 36 However, our findings indicate that high expression of SOCS-3 in CTCL cells may also play a role in acquisition of resistance to IFNa. In fact, we have recently shown that Stat3 is constitutively activated in vivo in the tumour stage of CTCL, particularly at the more advanced stage of the tumour. 37 Since SOCS-3 expression is dependent on Stat3 activation, SOCS-3 expression is possibly highest in the advanced stages of CTCL.
In summary, we here provide evidence that in CTCL cells SOCS-3 does not act as a tumour suppressor, as Stat3 activation, cell proliferation, and survival are not affected by SOCS-3 expression. Instead, SOCS-3 is able to downmodulate signalling from certain growth-inhibitory and Th1-promoting cytokines. Therefore, its expression seems beneficial to the malignant cells. Similar tumour-promoting mechanisms involving SOCS-3 may play a role in the pathogenesis of other malignancies as well. Therefore, SOCS-3 emerges as a novel attractive therapeutic target in CTCL and, perhaps, other types of cancer. 
